Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484884 | 0.90 | EIF2AK2 (0.62) | MAOBAHREGFRERBB2EIF2AK2 | |
| SCHEMBL11094738 | 0.83 | MAOB (0.53) | MAOBAHREGFRERBB2EIF2AK2 | |
| SCHEMBL5638486 | 0.82 | EIF2AK2 (0.61) | MAOBAHREIF2AK2GRIA1CACNG8 | |
| SCHEMBL9581631 | 0.81 | KIF11 (0.56) | MAOBAHREGFRERBB2EIF2AK2 | |
| SCHEMBL3484160 | 0.81 | PDE7A (0.55) | MAOBAHREGFRERBB2EIF2AK2 | |
| SCHEMBL22660 | 0.77 | AHR (0.61) | AHREIF2AK2GRIA1CACNG8PGR | |
| SCHEMBL11089100 | 0.76 | AHR (0.68) | MAOBAHREIF2AK2GRIA1CACNG8 | |
| Hydrochloric Acid SCHEMBL15206761 | 0.75 | AHR (0.59) | AHREIF2AK2GRIA1CACNG8PGR | |
| Bromide SCHEMBL9824774 | 0.75 | AHR (0.59) | AHREIF2AK2GRIA1CACNG8PGR | |
| SCHEMBL3484815 | 0.74 | EGFR (0.49) | AHREGFRERBB2GRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | MAOB 847/4885AHR 259/4885EGFR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.